FDA–EMA AI Principles

Artificial intelligence is moving deeper into drug development, and U.S. and European regulators now want it governed the same way on both sides of the Atlantic. (fda.gov) On January 14, 2026, the Food and Drug Administration and the European Medicines Agency published 10 joint principles for using AI in drug and biological product development. The agencies said the framework applies across the medicines lifecycle, from early research and clinical trials to manufacturing and post-market safety monitoring. (fda.gov) The FDA page lists the 10 themes: human-centric design, a risk-based approach, adherence to standards, clear context of use, multidisciplinary expertise, data governance and documentation, model design and development practices, risk-based performance assessment, life cycle management, and clear essential information. (fda.gov) In plain terms, regulators are telling sponsors to define what an AI system is supposed to do before they use it, document the data and design choices behind it, test whether it performs reliably for that exact job, and keep watching it after deployment. The FDA’s January 2025 draft guidance uses the same “context of use” concept and a risk-based credibility framework for AI-generated evidence submitted to support safety, effectiveness, or quality decisions. (fda.gov) That is a shift from treating AI as a generic software tool. In regulated drug evidence, the agencies are framing AI as a system that can change over time and therefore needs oversight, validation, change control, and records that inspectors can review. (fda.gov) The joint principles did not appear out of nowhere. The European Medicines Agency had already finalized a broader reflection paper on September 9 and 11, 2024, after a public consultation that ran from July 19 to December 31, 2023, covering AI use in discovery, non-clinical work, clinical trials, precision medicine, manufacturing, and post-authorization activities. (ema.europa.eu) The FDA, for its part, says its current approach was informed by more than 800 external comments, an August 6, 2024 public workshop, and experience with more than 500 submissions containing AI components between 2016 and 2023. That gives the new principles a practical base in actual filings, not just policy drafting. (fda.gov) The agencies are not banning AI in trials, manufacturing, or safety monitoring. They are setting expectations for how companies explain AI systems, justify their use, and show that the output is trustworthy enough to support decisions about whether a medicine is safe, effective, and made to quality standards. (ema.europa.eu) For drugmakers, contract research organizations, and software vendors, the practical message is that “black box” claims will be harder to defend in submissions and inspections. The more an AI tool influences regulated evidence, the more clearly its purpose, limits, monitoring, and human oversight will need to be documented. (fda.gov) The next step is not a single new rulebook but a thicker layer of guidance, standards, and review practice built around these 10 principles. The agencies describe the January 2026 document as a foundation for future harmonization, training, research, and consensus standards as AI use expands across the drug lifecycle. (fda.gov)